Supplementary funding to support the extension of the EDCTP-funded ETEC Vaccine Efficacy study

补充资金支持 EDCTP 资助的 ETEC 疫苗功效研究的扩展

• 批准号: MC_PC_23002
• 金额: $ 26.47万
• 依托单位: European Developing Countries
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_23002
• 关键词: Supplementary; funding; support; extension; EDCTP

"Supplementary funding to support the extension of the EDCTP-funded trial ""Field studies of an oral whole cell ETEC vaccine candidate in African toddlers and children: Assess efficacy and set parameters for pivotal Phase 3 trials (ETEC Vaccine Efficacy)"" held by Mr Björn Sjöstrand (Scandinavian Biopharma Holding AB, Sweden). Study delayed due to the negative impacts of the Covid-19 pandemic. ETVAX® is a killed whole-cell oral vaccine against ETEC. ETVAX® produces immunity by preventing ETEC bacteria from adhering to cells of the small intestine and interfering with the effects of ETEC toxins on these cells. Scientists recognize ETVAX as the most clinically advanced ETEC vaccine. The results of the Phase 1 study support the safety, tolerability, and immunogenicity of ETVAX® in adults and children in Zambia. https://scandinavianbiopharma.se/studies/study-oev-124-phase-i-descending-age-study-in-a-lmic/ and https://scandinavianbiopharma.se/studies/oev-128-phase-iib-study-in-children-6-18-months-in-a-lmic/"

“支持延长 EDCTP 资助试验的补充资金”“非洲幼儿和儿童口服全细胞 ETEC 候选疫苗的现场研究：评估功效并设定关键 3 期试验的参数（ETEC 疫苗功效）”” Björn Sjöstrand 先生（瑞典 Scandinavian Biopharma Holding AB）由于 Covid-19 大流行的负面影响而推迟了 ETVAX® 是一种灭活的全细胞口服药物。针对 ETEC 的疫苗 ETVAX® 通过阻止 ETEC 细菌粘附在小肠细胞上并干扰 ETEC 毒素对这些细胞的作用来产生免疫力。第一阶段研究的结果是，ETVAX 是临床上最先进的 ETEC 疫苗。支持赞比亚成人和儿童 ETVAX® 的安全性、耐受性和免疫原性。 https://scandinavianbiopharma.se/studies/study-oev-124-phase-i-descending-age-study-in-a-lmic/ 和 https://scandinavianbiopharma.se/studies/oev-128-phase-iib -儿童学习 6-18 个月在 LMIC/”